GlaxoSmithKline ROA 2006-2018 | GSK

Current and historical return on assets (ROA) values for GlaxoSmithKline (GSK) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. GlaxoSmithKline ROA for the three months ending September 30, 2018 was 9.96%.
GlaxoSmithKline ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $2.83B $76.36B 3.71%
2018-06-30 $2.57B $78.44B 3.36%
2018-03-31 $1.74B $78.15B 2.31%
2017-12-31 $1.98B $72.66B 2.66%
2017-09-30 $3.05B $76.96B 4.00%
2017-06-30 $2.52B $74.47B 3.31%
2017-03-31 $2.13B $73.37B 2.72%
2016-12-31 $1.24B $80.07B 1.55%
2016-09-30 $0.30B $77.21B 0.38%
2016-06-30 $0.07B $82.69B 0.09%
2016-03-31 $0.93B $78.06B 1.14%
2015-12-31 $12.77B $81.72B 15.25%
2015-09-30 $14.87B $82.36B 18.57%
2015-06-30 $14.68B $82.89B 19.24%
2015-03-31 $15.57B $87.93B 21.65%
2014-12-31 $4.44B $67.00B 6.69%
2014-09-30 $6.81B $67.35B 10.30%
2014-06-30 $7.73B $65.39B 11.86%
2014-03-31 $8.22B $65.72B 12.65%
2013-12-31 $8.56B $65.86B 13.13%
2013-09-30 $6.01B $63.72B 9.22%
2013-06-30 $6.25B $64.61B 9.58%
2013-03-31 $6.62B $66.64B 10.05%
2012-12-31 $7.30B $65.74B 11.18%
2012-09-30 $7.90B $63.91B 12.10%
2012-06-30 $8.28B $67.24B 12.55%
2012-03-31 $8.10B $64.10B 12.21%
2011-12-31 $8.41B $65.91B 12.48%
2011-09-30 $5.32B $66.75B 7.92%
2011-06-30 $5.21B $68.67B 7.78%
2011-03-31 $2.98B $68.17B 4.52%
2010-12-31 $2.60B $65.03B 3.92%
2010-09-30 $6.44B $66.10B 9.64%
2010-06-30 $6.60B $64.23B 9.82%
2010-03-31 $9.29B $69.57B 14.27%
2009-12-31 $8.92B $67.12B 14.43%
2009-09-30 $7.69B $68.04B 12.15%
2009-06-30 $7.93B $55.68B 12.73%
2009-03-31 $8.27B $56.32B 12.84%
2008-12-31 $9.23B $73.07B 14.09%
2008-09-30 $9.93B $64.23B 15.83%
2008-06-30 $10.15B $64.13B 16.74%
2008-03-31 $10.24B $60.41B 17.68%
2007-12-31 $10.60B $62.04B 20.60%
2007-09-30 $10.71B $55.92B 22.46%
2007-06-30 $10.69B $53.26B 23.31%
2007-03-31 $10.46B $34.55B 23.43%
2006-12-31 $10.15B $47.09B 21.03%
2006-09-30 $9.86B $48.47B 20.17%
2006-06-30 $9.40B $48.39B 19.50%
2006-03-31 $9.10B $49.05B 19.26%
2005-12-31 $8.74B $49.53B 19.06%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.650B $38.892B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $393.045B 18.43
Pfizer (PFE) United States $261.986B 14.77
Merck (MRK) United States $207.903B 18.02
Novartis AG (NVS) Switzerland $201.478B 17.27
AbbVie (ABBV) United States $132.627B 11.77
Eli Lilly (LLY) United States $121.292B 21.32
Sanofi (SNY) France $111.158B 13.76
Novo Nordisk (NVO) Denmark $110.447B 17.94
AstraZeneca (AZN) United Kingdom $97.922B 12.16
Bristol-Myers Squibb (BMY) United States $85.576B 14.09